Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TTK Healthcare's Enterprise Value is ₹4,871 Mil.
TTK Healthcare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹855 Mil. Therefore, TTK Healthcare's EV-to-EBIT ratio for today is 5.70.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, TTK Healthcare's Enterprise Value is ₹4,871 Mil.
TTK Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹943 Mil. Therefore, TTK Healthcare's EV-to-EBITDA ratio for today is 5.17.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, TTK Healthcare's Enterprise Value is ₹4,871 Mil.
TTK Healthcare's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹8,573 Mil. Therefore, TTK Healthcare's EV-to-Revenue ratio for today is 0.57.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
TTK Healthcare (BOM:507747) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
TTK Healthcare's current Enterprise Value is ₹4,871 Mil.
TTK Healthcare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹855 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
TTK Healthcare's current Enterprise Value is ₹4,871 Mil.
TTK Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹943 Mil.
TTK Healthcare's current Enterprise Value is ₹4,871 Mil.
TTK Healthcare's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,573 Mil.
TTK Healthcare's current Enterprise Value is ₹4,871 Mil.
TTK Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
TTK Healthcare's current Enterprise Value is ₹4,871 Mil.
TTK Healthcare's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTK Healthcare Enterprise Value Related Terms
TTK Healthcare Enterprise Value Historical Data
* Premium members only.
The historical data trend for TTK Healthcare's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:507747 vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, TTK Healthcare's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's Enterprise Value distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
TTK Healthcare's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTK Healthcare (BOM:507747) has a Enterprise Value of ₹4,871 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on TTK Healthcare and its competitors.
Is TTK Healthcare's Enterprise Value too high?
TTK Healthcare's current Enterprise Value is ₹4,871 Mil. Overall, TTK Healthcare has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's Enterprise Value compare to LLY and JNJ?
TTK Healthcare's Enterprise Value of ₹4,871 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on TTK Healthcare and its competitors. TTK Healthcare's current Enterprise Value is ₹4,871 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,454.83, compared to a current price of ₹990.05 — trading 31.9% below its estimated fair value. The current Enterprise Value is ₹4,871 Mil. TTK Healthcare's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current Enterprise Value is ₹4,871 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹990.05 is trading 31.9% below its estimated GF Value™ of ₹1,454.83.
GuruFocus considers TTK Healthcare to be Significantly Undervalued.
Key valuation signals for BOM:507747:
Enterprise Value: ₹4,871 Mil
GF Value™: ₹1,454.83 vs. price of ₹990.05 (31.9% below fair value)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
72GF Score
Get the complete analysis for BOM:507747
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
